All closed deals
Closed November 2025
VESSEL THERAPEUTICS
Peptide delivery across the blood–brain barrier.
Listed May 2025 · 188 days listing to close
RaisedCHF 3.5M
RoundSeed
SectorBiotech
What actually happened
A seven-angel syndicate is administratively heavier than one fund, and most founders cannot run it alone. The value here was structural: one convertible instrument, one set of terms, two closes six weeks apart, and a single point of contact so the founders kept working on the science rather than on the cap table.
What Deux Rives did
- Structured a single instrument across eight parties.
- Ran the syndicate process and the second close.
- Prepared the scientific pack for non-specialist angels.
- Set up reporting cadence post-close on the Trinity stack.
Deal shape
InstrumentConvertible loan, capped
CapCHF 14M
BoardObserver seat
SyndicateEight parties, two closes
Syndicate
LeadSyndicate of seven business angels, life-science operators
Co-investorCantonal innovation vehicle
Investor identities are described by type only. That is deliberate and permanent.